Juergen Barth

2.1k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Juergen Barth is a scholar working on Pathology and Forensic Medicine, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Juergen Barth has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 5 papers in Genetics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Juergen Barth's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Juergen Barth is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Juergen Barth collaborates with scholars based in Germany, Austria and United Kingdom. Juergen Barth's co-authors include Mathias Rummel, Wolfram Brugger, Christoph Losem, Axel Hinke, Manfred Welslau, Ulrich Kaiser, Eckhart Weidmann, Christina Balser, N. Niederle and Georg Maschmeyer and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Juergen Barth

16 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juergen Barth Germany	10	1.3k	913	784	208	146	17	1.4k
Ulrich von Grünhagen Germany	6	1.2k 1.0×	849 0.9×	789 1.0×	197 0.9×	151 1.0×	10	1.4k
Christina Balser Germany	11	1.3k 1.0×	903 1.0×	825 1.1×	219 1.1×	154 1.1×	18	1.6k
Dorothea Kofahl-Krause Germany	10	1.5k 1.1×	984 1.1×	921 1.2×	256 1.2×	164 1.1×	15	1.6k
J. Matthews United Kingdom	13	988 0.8×	664 0.7×	428 0.5×	158 0.8×	196 1.3×	20	1.1k
M. Dreyling Germany	16	1.2k 0.9×	773 0.8×	438 0.6×	261 1.3×	137 0.9×	22	1.3k
P. Solal-Céligny France	8	1.2k 0.9×	818 0.9×	539 0.7×	389 1.9×	155 1.1×	14	1.5k
Elisabeth Wassner-Fritsch Switzerland	12	1.1k 0.9×	743 0.8×	768 1.0×	124 0.6×	300 2.1×	20	1.3k
Charles Foussard France	12	885 0.7×	601 0.7×	356 0.5×	195 0.9×	262 1.8×	22	1.0k
Alina S. Gerrie Canada	18	800 0.6×	465 0.5×	422 0.5×	260 1.3×	118 0.8×	110	1.1k
Sophie Lefort France	6	994 0.8×	698 0.8×	352 0.4×	283 1.4×	167 1.1×	10	1.3k

Countries citing papers authored by Juergen Barth

Since Specialization

Citations

This map shows the geographic impact of Juergen Barth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Barth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Barth more than expected).

Fields of papers citing papers by Juergen Barth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen Barth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Barth. The network helps show where Juergen Barth may publish in the future.

Co-authorship network of co-authors of Juergen Barth

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen Barth. A scholar is included among the top collaborators of Juergen Barth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen Barth. Juergen Barth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Rummel, Mathias, Michael Koenigsmann, Kai Uwe Chow, et al.. (2018). Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. Journal of Clinical Oncology. 36(15_suppl). 7515–7515. 14 indexed citations

Weiß, Lukas, Thomas Melchardt, Alexander Egle, et al.. (2017). Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. Annals of Hematology. 96(7). 1155–1162. 3 indexed citations

Rummel, Mathias, Georg Maschmeyer, Arnold Ganser, et al.. (2017). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.. Journal of Clinical Oncology. 35(15_suppl). 7501–7501. 47 indexed citations

Rummel, Mathias, Wolfgang Knauf, Martin Göerner, et al.. (2016). Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).. Journal of Clinical Oncology. 34(15_suppl). 7503–7503. 52 indexed citations

Rummel, Mathias, Ulrich Kaiser, Christina Balser, et al.. (2015). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology. 17(1). 57–66. 110 indexed citations

Zohren, Fabian, Ingmar Bruns, Sabrina Pechtel, et al.. (2015). Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 126(12). 1407–1414. 26 indexed citations

Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet. 381(9873). 1203–1210. 962 indexed citations breakdown →

Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2012). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.. Journal of Clinical Oncology. 30(15_suppl). 3–3. 35 indexed citations

Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2012). Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.. Blood. 120(21). 2724–2724. 1 indexed citations

10.

Rummel, Mathias, Christian Lerchenmüller, Richard Greil, et al.. (2012). Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).. Blood. 120(21). 2739–2739. 16 indexed citations

11.

Dickler, Maura N., M Volm, Yelena Novik, et al.. (2011). Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors.. Journal of Clinical Oncology. 29(15_suppl). 1100–1100. 1 indexed citations

12.

Luke, Jason J., Leigh Ann Callahan, C. H. Darby, et al.. (2011). Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis.. Journal of Clinical Oncology. 29(15_suppl). 3069–3069. 1 indexed citations

13.

Rummel, Mathias, Ulrich Kaiser, Christina Balser, et al.. (2010). Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 116(21). 856–856. 26 indexed citations

14.

Zohren, Fabian, Ingmar Bruns, Juergen Barth, et al.. (2009). Quantitative Real-Time PCR of Peripheral Blood t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in Patients with Follicular Lymphoma.. Blood. 114(22). 441–441. 1 indexed citations

15.

Brugger, Wolfram, Georg Maschmeyer, Dorothea Kofahl-Krause, et al.. (2009). Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany).. Blood. 114(22). 2679–2679. 8 indexed citations

16.

Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2009). Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).. Blood. 114(22). 405–405. 112 indexed citations

17.

Braun, Wolfgang, et al.. (1970). [Observations and results of a double-target experiment on the concept of multi-stage cancer therapy using healthy subjects].. PubMed. 25(8). 333–46. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact